Pharsight

Drugs that contain Cyclosporine

1. Cequa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Aug, 2033

(9 years from now)

US10441630 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(9 years from now)

US9937225 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(9 years from now)

US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(13 years from now)

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

CEQUA family patents

Family Patents

2. Restasis patents expiration

RESTASIS's oppositions filed in EPO
RESTASIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642556 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8633162 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8685930 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8648048 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8629111 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US9248191 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8292129 ABBVIE Dispensing device
Feb, 2031

(6 years from now)

US8561859 ABBVIE Dispensing device
Apr, 2032

(8 years from now)

US9676525 ABBVIE Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Feb, 2034

(9 years from now)

US9669974 ABBVIE Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
May, 2034

(10 years from now)

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's drug patent expiration?
More Information on Dosage

RESTASIS family patents

Family Patents

3. Verkazia patents expiration

Can you believe VERKAZIA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524779 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 10 months from now)

US9956289 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 10 months from now)

US9220694 SANTEN Emulsion compositions containing cetalkonium chloride
Jan, 2026

(1 year, 10 months from now)

US7973081 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 10 months from now)

US11612658 SANTEN Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same
Jan, 2026

(1 year, 10 months from now)

US8298568 SANTEN Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Nov, 2027

(3 years from now)

US9132071 SANTEN Compositions containing quaternary ammonium compounds
Jun, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 23, 2028
New Product (NP) Jun 23, 2024

Market Authorisation Date: 23 June, 2021

Treatment: For the treatment of vernal keratoconjunctivitis in children and adults

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage

VERKAZIA family patents

Family Patents

4. Vevye patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8614178 NOVALIQ GMBH Pharmaceutical composition for treatment of dry eye syndrome
Dec, 2030

(6 years from now)

US10813976 NOVALIQ GMBH Ophthalmic compositions comprising ciclosporin
Sep, 2037

(13 years from now)

US11154513 NOVALIQ GMBH Semifluorinated compounds
Nov, 2038

(14 years from now)

US11413323 NOVALIQ GMBH Ophthalmic composition for treatment of dry eye disease
Oct, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 30, 2026

Market Authorisation Date: 30 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of dry eye disease (ded)

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

VEVYE family patents

Family Patents